Cognitive Testing in Clinical Drug Trials: Successful Test Selection and Integration Training Course

Overview

Cognitive assessment has long been a key efficacy measure in clinical trials of indications such as Alzheimer’s disease. In the past few years, the use of cognitive efficacy measures has been extended to indications including Schizophrenia, Depression and Lewy body Dementias. The use of cognitive assessment has also been extended to the assessment of safety, especially in cardiology. 

Cognitive assessment has been employed with variable success and a hallmark of failed examples has been the use of tests with poor reliability, validity and sensitivity. In this webinar we will review examples of both successful and failed case studies. We will conclude with recommendations for cognitive test selection and its successful integration into clinical drug trials.

This is an excellent opportunity to hear from a renowned cognition expert and gain a better understanding on the selection and successful integration of cognitive testing into therapeutic development programmes.

Benefits of Attending

• Understand the increasing importance of cognitive testing in clinical drug trials
• Learn more about cognitive test selection and how to successfully integrate cognitive assessment in therapeutic  development programmes
• Gain an opportunity  to discuss the complexities of cognitive assessment with an expert in this field

Who Should Attend?

• Sponsor personnel responsible for cognitive test selection and integration
• CRO and site personnel involved in CNS clinical trials
• Industry analysts, regulators, journalists and anyone interested in discovering more about cognitive testing in clinical trials

Enrol or reserve